• PTEN inactivation has distinct effects on the signalling properties of EGFR and MET and their response to kinase inhibitors 

  Matucci, I (2020-09-30)

  Receptor tyrosine kinases (RTKs) are a family of cell-surface receptors that play a major role in regulating pro-proliferative and pro-survival signalling pathways, such as the Phosphoinositide 3-kinase (PI3K/Akt) pathway. ...
• The molecular characterisation of MET addiction in lung cancer 

  Coleman, N (2020-08-31)

  The traditional classification of lung cancer has been radically altered with increased understanding of the molecular alterations and genomic biomarkers that drive the development of the disease. Whilst molecularly targeted ...
• Circulating cell-free DNA methylation analysis of metastatic prostate cancer 

  Wu, A (2020-03-31)

  Introduction; Materials and methods; Deciphering global plasma DNA methylation variance in metastatic prostate cancer; Implementation of a methylation signature for tracking and detection of prostate cancer in plasma; ...
• Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. 

  Gallon, J; Loomis, E; Curry, E; Martin, N; Brody, L; Garner, I; Brown, R; Flanagan, JM (2021-06-05)

  <h4>Background</h4>Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition ...
• Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. 

  Ledermann, JA; Embleton-Thirsk, AC; Perren, TJ; Jayson, GC; Rustin, GJS; Kaye, SB; Hirte, H; Oza, A; Vaughan, M; Friedlander, M; González-Martín, A; Deane, E; Popoola, B; Farrelly, L; Swart, AM; Kaplan, RS; Parmar, MKB; ICON6 collaborators

  <h4>Background</h4>Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first ...
• Magnetic resonance image guided adaptive radiotherapy for gynaecological and rectal cancer 

  White, I (2020-11-30)

  Multiple challenges exist in radiotherapy for gynaecological and rectal cancer. These lead to uncertainty and error in dose delivered to the tumour target and organs at risk (OARs). Adequate planning target volume (PTV) ...
• Investigating the molecular mechanisms of fraction size sensitivity in irradiated cells 

  McBay, D (2020-09-30)

  Fractionated radiotherapy is used clinically when it spares healthy tissue relative to the cancer; the healthy tissue is described as more fraction size sensitive. However, a molecular understanding of the mechanisms that ...
• Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. 

  Ali, A; Hoyle, A; Haran, ÁM; Brawley, CD; Cook, A; Amos, C; Calvert, J; Douis, H; Mason, MD; Dearnaley, D; Attard, G; Gillessen, S; Parmar, MKB; Parker, CC; Sydes, MR; James, ND; Clarke, NW (2021-02-18)

  <h4>Importance</h4>Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit ...
• Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. 

  Natoli, M; Gallon, J; Lu, H; Amgheib, A; Pinato, DJ; Mauri, FA; Marafioti, T; Akarca, AU; Ullmo, I; Ip, J; Aboagye, EO; Brown, R; Karadimitris, A; Ghaem-Maghami, S

  <h4>Background</h4>Endogenous retroviruses (ERVs) play a role in a variety of biological processes, including embryogenesis and cancer. DNA methyltransferase inhibitors (DNMTi)-induced ERV expression triggers interferon ...
• Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. 

  Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; de Bono, JS; Attard, G; Chowdhury, S; Cross, WR; Dearnaley, DP; Brawley, CD; Gilson, C; Ingleby, F; Gillessen, S; Aebersold, DM; Jones, RJ; Matheson, D; Millman, R; Mason, MD; Ritchie, AWS; Russell, M; Douis, H; Parmar, MKB; Sydes, MR; Clarke, NW; STAMPEDE Investigators

  <h4>Background</h4>Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen ...
• Genetic predisposition to prostate cancer: an update. 

  Ni Raghallaigh, H; Eeles, R (2021-01-24)

  Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ...
• The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. 

  Hamilton, RJ; Ding, K; Crook, JM; O'Callaghan, CJ; Higano, CS; Dearnaley, DP; Horwitz, EM; Goldenberg, SL; Gospodarowicz, MK; Klotz, L (2020-12-31)

  <h4>Background</h4>Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report ...
• Prostate cancer - Advantages and disadvantages of MR-guided RT. 

  Murray, J; Tree, AC

  External beam radiotherapy for prostate cancer is an optimal treatment choice for men with localised prostate cancer and is associated with long term disease control in most patients. Image-guided prostate radiotherapy is ...
• Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037) 

  Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; McLachlan, J; Hall, M; Tunariu, N; Attygalle, A; Lima, JPDSN; Perry, S; Chatfield, P; Hills, M; Kaye, S; Attard, G; Dowsett, M; Bliss, JM (SAGE PUBLICATIONS LTD, 2020-12-01)
• Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP trial. 

  Brand, DH; Brüningk, SC; Wilkins, A; Fernandez, K; Naismith, O; Gao, A; Syndikus, I; Dearnaley, DP; Tree, AC; van As, N; Hall, E; Gulliford, S; CHHiP Trial Management Group (2021-01-04)

  <h4>Purpose</h4>Changes in fraction size of external beam radiotherapy (EBRT) exert non-linear impacts on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues ...
• Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. 

  Aladwani, M; Lophatananon, A; Robinson, F; Rahman, A; Ollier, W; Kote-Jarai, Z; Dearnaley, D; Koveela, G; Hussain, N; Rageevakumar, R; Keating, D; Osborne, A; Dadaev, T; Brook, M; British Association of Urological Surgeons’ Section of Oncology; Eeles, R; Eeles, R; Muir, KR (2020-01)

  <h4>Introduction</h4>Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association ...
• NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. 

  Hall, WA; Paulson, E; Davis, BJ; Spratt, DE; Morgan, TM; Dearnaley, D; Tree, AC; Efstathiou, JA; Harisinghani, M; Jani, AB; Buyyounouski, MK; Pisansky, TM; Tran, PT; Karnes, RJ; Chen, RC; Cury, FL; Michalski, JM; Rosenthal, SA; Koontz, BF; Wong, AC; Nguyen, PL; Hope, TA; Feng, F; Sandler, HM; Lawton, CAF (2021-01)

  <h4>Purpose</h4>In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing ...
• Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) 

  James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; Gale, J; Hetherington, J; Hoskin, PJ; Jones, RJ; Laing, R; Lester, JF; McLaren, D; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, JM; Strebel, RT; Thalmann, GN; Mason, MD; Sydes, MR (2015-06)
• Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials. 

  Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; Greer, PB; Holloway, LC; Dowling, JA; Jameson, MG; Roach, D; Joseph, DJ; Gulliford, SL; Dearnaley, DP; Sydes, MR; Hall, E; Ebert, MA (2020-01)

  <b>Purpose:</b> Dose information from organ sub-regions has been shown to be more predictive of genitourinary toxicity than whole organ dose volume histogram information. This study aimed to identify anatomically-localized ...
• Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. 

  Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; Greer, PB; Holloway, LC; Dowling, JA; Jameson, MG; Roach, D; Joseph, DJ; Gulliford, SL; Dearnaley, DP; Sydes, MR; Hall, E; Ebert, MA (2020-12)

  <h4>Purpose</h4>Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of ...

View more